Long non‐coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer

• Published in: Clinical and translational medicine Vol. 11; no. 6; pp. e421 - n/a
• Main Authors: Shin, Min‐Kyue, Kim, Jungmin, Kim, Dachan, Lee, Sung Hwan, Shin, Ji‐Hyun, Jeong, Yun Seong, Sohn, Bo Hwa, Kim, Jimin, Kim, Seong‐Ryong, Ajani, Jaffer A., Lee, Ju‐Seog, Cheong, Jae‐Ho
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.06.2021; John Wiley and Sons Inc; Wiley
• Subjects: Biomarkers; Biomarkers, Tumor - genetics; Cancer therapies; Chemotherapy; Chemotherapy, Adjuvant - mortality; Clinical outcomes; Drugs; Epstein-Barr virus; Follow-Up Studies; Gastric cancer; Gastroenterology; Gene expression; Gene Expression Regulation, Neoplastic; Genomes; Genotype & phenotype; Grants; Humans; Immune Checkpoint Inhibitors - therapeutic use; immunotherapy; Kinases; Letter to Editor; long non‐coding RNA (lncRNA); Medical prognosis; Medical research; Prognosis; Retrospective Studies; RNA, Long Noncoding - genetics; Stomach Neoplasms - drug therapy; Stomach Neoplasms - genetics; Stomach Neoplasms - pathology; Survival Rate; Tumors; ZNF667‐AS1; gastric cancer; long non-coding RNA (lncRNA); chemotherapy; prognosis; ZNF667-AS1; immunotherapy
• ISSN: 2001-1326; 2001-1326
• DOI: 10.1002/ctm2.421

Owing to the small sample size and short follow-up period in the TCGA cohort, prognostic associations of the LNC6 subtypes were evaluated in independent public cohorts (n = 1,933; Table S1). Because lncRNA expression data from RNA sequencing are available for only TCGA among large-scale cohorts, we used LNC6 subtype-specific mRNA gene signature (Figures 1A and 1B). In agreement with this, silencing ZNF667-AS1 increased the expression of an epithelial marker (E-cadherin) and decreased the expression of mesenchymal markers (N-cadherin and vimentin) (Figure 4A). [...]this increased sensitivity to drugs commonly used for GC treatment – oxaliplatin and 5-FU (Figure 4B). Significant association of lncRNA expression with prognosis and therapeutic responses indicate that it could be used to elaborate precision medicine for GC. [...]functional association of a lncRNA with clinically relevant phenotypes supports the notion of lncRNA-targeting therapeutics.